ClinicalTrials.gg
CompletedNCT00089661Updated Oct 17, 2018Results posted

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

A Phase 3 interventional study of Placebo and AMG 162 / Denosumab in Breast Cancer, Low Bone Mineral Density and Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Enrollment
8th of 24
252 · median 53
Started
2004
with 1 other
Phase 3
9 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
8 of 24
Amgen

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 1st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

03

Conditions studied

  • Breast Cancer
  • Low Bone Mineral Density
  • Osteopenia

Keywords

  • Breast Cancer
  • Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC
  • osteopenia
  • Low bone density
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  • or cytologically confirmed adenocarcinoma of the breast
  • Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study
  • All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer Institution (NCI) (CTCAE)
  • Female > 18 years of age
  • Performance status 0 and 1
  • Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5
  • Subject is willing and able to provide signed consent before any study-specific procedure

Other criteria also apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    AMG 162 / Denosumab

    Drug: AMG 162 / Denosumab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months

  • DrugAMG 162 / Denosumab

    Drug page: Denosumab

    60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

Secondary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 6 months

  2. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

  3. Total Hip Bone Mineral Density Percent Change From Baseline at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 6 months

  4. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

  5. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 6 months

07

Results

Posted Jan 26, 2010

Participant flow

Participant flow — Overall Study
MilestoneDenosumab 60 mg Q6MPlacebo
Started127125
Completed10699
Not completed2126
Withdrew: Adverse event02
Withdrew: Death10
Withdrew: Lost to follow-up03
Withdrew: Withdrawal by subject119
Withdrew: Disease progression13
Withdrew: Ineligibility determined44
Withdrew: Noncompliance24
Withdrew: Other21

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 124.8 (4.3 to 5.4)-.7 (-1.3 to -.1)
Statistical analysis
  • Denosumab 60 mg Q6M vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): 5.5 · 95% CI 4.8 to 6.3
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
6 months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 6
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 63.7 (3.2 to 4.2)-.6 (-1.1 to -.1)
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Total Hip Bone Mineral Density Percent Change From Baseline at Month 123.1 (2.6 to 3.5)-.7 (-1.1 to -.2)
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
6 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 6
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Total Hip Bone Mineral Density Percent Change From Baseline at Month 62.3 (1.9 to 2.8)-.4 (-.8 to .1)
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 121.9 (1.1 to 2.6)-.6 (-1.4 to .2)
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 6

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
6 months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 6
Percent Change from BaselineDenosumab 60 mg Q6MPlacebo
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 61.2 (.5 to 1.9)-.9 (-1.6 to -.2)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—11/120 (9.2%)108/120 (90%)
Denosumab 60 mg Q6M—19/129 (14.7%)117/129 (90.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPlaceboDenosumab 60 mg Q6M
CholelithiasisHepatobiliary disorders2/1200/129
OsteoarthritisMusculoskeletal and connective tissue disorders0/1202/129
Atrial fibrillationCardiac disorders1/1200/129
Cardiac failure congestiveCardiac disorders1/1200/129
Myocardial ischaemiaCardiac disorders1/1200/129
GoitreEndocrine disorders1/1200/129
FaecalomaGastrointestinal disorders1/1200/129
Large intestine perforationGastrointestinal disorders1/1200/129
CholecystitisHepatobiliary disorders1/1201/129
PneumoniaInfections and infestations1/1200/129
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlaceboDenosumab 60 mg Q6M
ArthralgiaMusculoskeletal and connective tissue disorders30/12031/129
Pain in extremityMusculoskeletal and connective tissue disorders14/12019/129
FatigueGeneral disorders17/12017/129
Back painMusculoskeletal and connective tissue disorders15/12018/129
InsomniaPsychiatric disorders14/12012/129
ConstipationGastrointestinal disorders11/12015/129
CoughRespiratory, thoracic and mediastinal disorders5/12013/129
NauseaGastrointestinal disorders11/12010/129
DepressionPsychiatric disorders11/1207/129
MyalgiaMusculoskeletal and connective tissue disorders5/12011/129

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Denosumab 60 mg Q6MPlaceboTotal
Mean59.2 ± 8.959.7 ± 9.759.5 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab 60 mg Q6MPlaceboTotal
Female127125252
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009 Nov;118(1):81-7. doi: 10.1007/s10549-009-0352-y. Epub 2009 Mar 24. PubMed 19308727 ↗
  • Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25. PubMed 18725648 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2004 to primary completion in May 2007, 31 months.

Results were first posted in Jan 2010, 2 years 8 months after primary completion. A results delay was requested in Nov 2009.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 31 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2004
First posted
Aug 11, 2004
StartActual
Oct 1, 2004
Primary completionActual
May 11, 2007
CompletionActual
May 27, 2009
Results delay requested
Nov 19, 2009
Results first posted
Jan 26, 2010
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00089661
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 11, 2004
Start date
Oct 1, 2004
Primary completion
May 11, 2007
Completion
May 27, 2009
Results posted
Jan 26, 2010
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion